TABLE 2.
Care cascade outcomes, by clinic and total
|
Total N = 633 n (%) |
MLF Than Sitt Charity Clinic n = 380 n (%) |
Burnet Institute Thingangyun Clinic n = 253 n (%) |
Pearson's Chi‐square/Fisher's exact test (P‐value) | |
|---|---|---|---|---|
| Positive for anti‐hepatitis C antibodies | 606 (96) | 368 (97) | 238 (94) | P = .091 |
| Received GeneXpert(R) RNA test a | 606 (100) | 368 (100) | 238 (100) | NA |
| Positive for hepatitis C RNA | 535 (88) | 331 (90) | 204 (86) | P = .114 |
| Number of RNA‐positive participants: | 535 | 331 | 204 | |
| Patients who underwent specialist review b | 30 (6) | 13 (4) | 17 (8) | P = .027 |
| Patients eligible for DAA treatment | 489 (91) | 312 (94) | 177 (87) | P = .003 |
| Patients initiated on DAA treatment a | 488 (91) | 312 (94) | 176 (86) | P = .002 |
| Patients who initiated DAA treatment: | 488 | 312 | 176 | |
| Patients who completed treatment per protocol a | 477 (98) | 308 (99) | 169 (96) | P = .054 |
| Patients who achieve SVR12 a (ITT analysis) | 421 (86) | 275 (88) | 146 (83) | P = .110 |
| Patients who complete treatment per protocol: | 477 | 308 | 169 | |
| Patients who achieve SVR12 (per protocol analysis) a | 419 (88) | 275 (89) | 144 (85) | P = .192 |
| Patients who underwent SVR12 testing: | 456 | 295 | 161 | |
| Patients who achieve SVR12 a (mITT analysis) | 421 (92) | 275 (93) | 146 (91) | P = .331 |
Per protocol analysis = analysis of SVR12 achievement, among those who completed treatment.
ITT analysis = analysis of SVR12 achievement among all those initiated on DAA treatment.
mITT analysis = analysis of SVR12 achievement, only among those tested for SVR12.
a
Primary outcome measures.
b
Secondary outcome measures.